Research Analysts Set Expectations for MannKind Q3 Earnings

Key Points

• HC Wainwright lowered MannKind’s Q3 2026 EPS estimate to a loss of $0.10 from a prior loss of $0.05, while forecasting full-year 2026 EPS of negative $0.27 and breakeven earnings in 2028.
• Despite the weaker earnings outlook, analyst sentiment remains broadly positive: seven analysts rate MannKind a Buy, two rate it Hold and one rates it Sell, resulting in a consensus “Moderate Buy” rating and a $9.22 target price.
• MannKind shares opened at $3.73, down 3.1%, while institutional investors own nearly half the company. Director Steven B. Binder also sold 39,051 shares at an average price of $4.06.

MannKind Corporation (NASDAQ:MNKD - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for MannKind in a report issued on Thursday, August 6th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will post earnings of ($0.10) per share for the quarter, down from their prior estimate of ($0.05). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for MannKind's current full-year earnings is ($0.08) per share. HC Wainwright also issued estimates for MannKind's Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.06) EPS and FY2028 earnings at $0.00 EPS.

Several other research analysts have also recently commented on MNKD. Wells Fargo & Company lowered their target price on shares of MannKind from $14.00 to $13.00 and set an "overweight" rating on the stock in a report on Thursday, August 6th. Royal Bank Of Canada increased their target price on MannKind from $3.50 to $4.75 and gave the stock a "sector perform" rating in a report on Thursday, May 7th. Zacks Research raised shares of MannKind from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 5th. Mizuho decreased their target price on shares of MannKind from $8.00 to $7.00 and set an "outperform" rating on the stock in a report on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of MannKind in a report on Wednesday, July 8th. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, MannKind currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.22.

MannKind Stock Down 3.1%

Shares of MannKind stock opened at $3.73 on Friday. The business's 50 day moving average is $3.97 and its 200-day moving average is $3.71. The stock has a market cap of $1.20 billion, a P/E ratio of -28.69 and a beta of 1.12. MannKind has a 12-month low of $2.23 and a 12-month high of $6.51.

Insider Buying and Selling

In related news, Director Steven B. Binder sold 39,051 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $4.06, for a total value of $158,547.06. Following the transaction, the director directly owned 785,867 shares in the company, valued at $3,190,620.02. This trade represents a 4.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 2.60% of the company's stock.

Institutional Trading of MannKind

A number of institutional investors have recently added to or reduced their stakes in MNKD. AQR Capital Management LLC increased its stake in MannKind by 19.8% in the first quarter. AQR Capital Management LLC now owns 55,333 shares of the biopharmaceutical company's stock valued at $278,000 after acquiring an additional 9,160 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of MannKind by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company's stock worth $1,059,000 after acquiring an additional 6,079 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in MannKind by 8.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company's stock worth $3,374,000 after acquiring an additional 53,202 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in MannKind by 42.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,352,017 shares of the biopharmaceutical company's stock worth $5,057,000 after purchasing an additional 404,842 shares in the last quarter. Finally, Prudential Financial Inc. boosted its position in shares of MannKind by 84.8% during the second quarter. Prudential Financial Inc. now owns 37,381 shares of the biopharmaceutical company's stock valued at $140,000 after buying an additional 17,150 shares during the last quarter. Hedge funds and other institutional investors own 49.55% of the company's stock.

Key Headlines Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: A Seeking Alpha analysis argued that two new FDA approvals could significantly accelerate growth for two of MannKind’s established products. The company also benefits from three revenue streams, while its existing liquidity may fund operations and product launches for roughly 2.3 years. MannKind: New Approvals Majorly Increase MannKind's Prospects
• Neutral Sentiment: HC Wainwright continues to rate MannKind Buy, suggesting the analyst sees longer-term upside despite near-term earnings revisions. The firm forecasts a path toward profitability, with projected EPS of $0.27 in 2029 and $0.68 in 2030, though both estimates were reduced. MannKind analyst estimates
• Negative Sentiment: HC Wainwright lowered its EPS forecast for the third quarter of 2026 to a loss of $0.10 from a loss of $0.05, and reduced its fourth-quarter estimate to a loss of $0.06 from $0.05. These changes point to weaker near-term profitability than previously expected. MannKind quarterly earnings estimates
• Negative Sentiment: The analyst also cut full-year 2026 EPS expectations to a loss of $0.27 from a loss of $0.18, and reduced the 2027 forecast to a loss of $0.06 from projected earnings of $0.04. The 2028 estimate was lowered to breakeven from $0.12 per share. MannKind annual earnings estimates
• Negative Sentiment: Longer-term estimates were also reduced: 2029 EPS was cut to $0.27 from $0.39, and 2030 EPS to $0.68 from $0.82. Although profitability remains part of the outlook, the revisions imply more cautious expectations for MannKind’s future earnings growth. MannKind long-term earnings estimates

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source